FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115465348> ?p ?o ?g. }

• W2115465348 endingPage "5453" @default.
• W2115465348 startingPage "5448" @default.
• W2115465348 abstract "Purpose This multicenter, phase II study was conducted to evaluate the activity of amrubicin, a topoisomerase II inhibitor, against refractory or relapsed small-cell lung cancer (SCLC). Patients and Methods SCLC patients with measurable disease who had been treated previously with at least one platinum-based chemotherapy regimen and had an Eastern Cooperative Oncology Group performance status of 0 to 2 were eligible. Two groups of patients were selected: patients who experienced first-line treatment failure less than 60 days from treatment discontinuation (refractory group), and patients who responded to first-line treatment and experienced disease progression ≥ 60 days after treatment discontinuation (sensitive group). Amrubicin was administered as a 5-minute daily intravenous injection at a dose of 40 mg/m 2 for 3 consecutive days, every 3 weeks. Results Between June 2003 and December 2004, 60 patients (16 refractory and 44 sensitive) were enrolled. The median number of treatment cycles was four (range, one to eight). Grade 3 or 4 hematologic toxicities comprised neutropenia (83%), thrombocytopenia (20%), and anemia (33%). Febrile neutropenia was observed in three patients (5%). Nonhematologic toxicities were mild. No treatment-related death was observed. The overall response rates were 50% (95% CI, 25% to 75%) in the refractory group, and 52% (95% CI, 37% to 68%) in the sensitive group. The progression-free survival, overall survival, and 1-year survival in the refractory group and the sensitive group were 2.6 and 4.2 months, 10.3 and 11.6 months, and 40% and 46%, respectively. Conclusion Amrubicin exhibits significant activity against SCLC, with predictable and manageable toxicities; this agent deserves to be studied more extensively in additional trials." @default.
• W2115465348 created "2016-06-24" @default.
• W2115465348 creator A5004024254 @default.
• W2115465348 creator A5017693924 @default.
• W2115465348 creator A5024660569 @default.
• W2115465348 creator A5027129364 @default.
• W2115465348 creator A5027580659 @default.
• W2115465348 creator A5034187210 @default.
• W2115465348 creator A5044442302 @default.
• W2115465348 creator A5045329864 @default.
• W2115465348 creator A5045893818 @default.
• W2115465348 creator A5052605297 @default.
• W2115465348 creator A5054048883 @default.
• W2115465348 creator A5058088814 @default.
• W2115465348 creator A5064455488 @default.
• W2115465348 creator A5065387771 @default.
• W2115465348 creator A5067259938 @default.
• W2115465348 creator A5078641782 @default.
• W2115465348 creator A5084744867 @default.
• W2115465348 creator A5085904437 @default.
• W2115465348 creator A5086351004 @default.
• W2115465348 date "2006-12-01" @default.
• W2115465348 modified "2023-10-05" @default.
• W2115465348 title "Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301" @default.
• W2115465348 cites W1800874491 @default.
• W2115465348 cites W1919288105 @default.
• W2115465348 cites W1932169383 @default.
• W2115465348 cites W1952431753 @default.
• W2115465348 cites W1980713819 @default.
• W2115465348 cites W1981137973 @default.
• W2115465348 cites W1985290232 @default.
• W2115465348 cites W1998353507 @default.
• W2115465348 cites W2015435594 @default.
• W2115465348 cites W2033060690 @default.
• W2115465348 cites W2051804117 @default.
• W2115465348 cites W2060818162 @default.
• W2115465348 cites W2082203970 @default.
• W2115465348 cites W2083904374 @default.
• W2115465348 cites W2089993835 @default.
• W2115465348 cites W2103786242 @default.
• W2115465348 cites W2108882850 @default.
• W2115465348 cites W2139248078 @default.
• W2115465348 cites W2160012348 @default.
• W2115465348 cites W2185382808 @default.
• W2115465348 cites W2323020638 @default.
• W2115465348 cites W2913381773 @default.
• W2115465348 cites W332202582 @default.
• W2115465348 cites W4233567369 @default.
• W2115465348 cites W4293241248 @default.
• W2115465348 doi "https://doi.org/10.1200/jco.2006.08.4145" @default.
• W2115465348 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17135647" @default.
• W2115465348 hasPublicationYear "2006" @default.
• W2115465348 type Work @default.
• W2115465348 sameAs 2115465348 @default.
• W2115465348 citedByCount "209" @default.
• W2115465348 countsByYear W21154653482012 @default.
• W2115465348 countsByYear W21154653482013 @default.
• W2115465348 countsByYear W21154653482014 @default.
• W2115465348 countsByYear W21154653482015 @default.
• W2115465348 countsByYear W21154653482016 @default.
• W2115465348 countsByYear W21154653482017 @default.
• W2115465348 countsByYear W21154653482018 @default.
• W2115465348 countsByYear W21154653482019 @default.
• W2115465348 countsByYear W21154653482020 @default.
• W2115465348 countsByYear W21154653482021 @default.
• W2115465348 countsByYear W21154653482022 @default.
• W2115465348 countsByYear W21154653482023 @default.
• W2115465348 crossrefType "journal-article" @default.
• W2115465348 hasAuthorship W2115465348A5004024254 @default.
• W2115465348 hasAuthorship W2115465348A5017693924 @default.
• W2115465348 hasAuthorship W2115465348A5024660569 @default.
• W2115465348 hasAuthorship W2115465348A5027129364 @default.
• W2115465348 hasAuthorship W2115465348A5027580659 @default.
• W2115465348 hasAuthorship W2115465348A5034187210 @default.
• W2115465348 hasAuthorship W2115465348A5044442302 @default.
• W2115465348 hasAuthorship W2115465348A5045329864 @default.
• W2115465348 hasAuthorship W2115465348A5045893818 @default.
• W2115465348 hasAuthorship W2115465348A5052605297 @default.
• W2115465348 hasAuthorship W2115465348A5054048883 @default.
• W2115465348 hasAuthorship W2115465348A5058088814 @default.
• W2115465348 hasAuthorship W2115465348A5064455488 @default.
• W2115465348 hasAuthorship W2115465348A5065387771 @default.
• W2115465348 hasAuthorship W2115465348A5067259938 @default.
• W2115465348 hasAuthorship W2115465348A5078641782 @default.
• W2115465348 hasAuthorship W2115465348A5084744867 @default.
• W2115465348 hasAuthorship W2115465348A5085904437 @default.
• W2115465348 hasAuthorship W2115465348A5086351004 @default.
• W2115465348 hasConcept C121332964 @default.
• W2115465348 hasConcept C126322002 @default.
• W2115465348 hasConcept C141071460 @default.
• W2115465348 hasConcept C142424586 @default.
• W2115465348 hasConcept C143998085 @default.
• W2115465348 hasConcept C2776256026 @default.
• W2115465348 hasConcept C2776694085 @default.
• W2115465348 hasConcept C2777063308 @default.
• W2115465348 hasConcept C2778715236 @default.
• W2115465348 hasConcept C2778850193 @default.
• W2115465348 hasConcept C2781413609 @default.

• next